

Number 628 • August 2016

## Product supply shortage addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Sandoz Canada Inc. and Teva Canada Limited that the shortages of Sandoz Quetiapine XRT 50 mg Extended-Release Tablet (DIN 02407671) and Teva-Quetiapine XR 50 mg Extended-Release Tablet (DIN 02395444) respectively have been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 5, 2016.** 

## **QUETIAPINE FUMARATE**

## **50 MG EXTENDED-RELEASE TABLET**

00002407671	SANDOZ QUETIAPINE XRT	SDZ	\$ 0.3950
00002395444	TEVA-QUETIAPINE XR	TEV	\$ 0.3950
00002300184	SEROQUEL XR	AZC	\$ 1.0003

## When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

**780-498-8370** (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit https://www.ab.bluecross.ca/providers/pharmacy-home.php** 



